GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Broncus Holding Corp (HKSE:02216) » Definitions » Gross Profit

Broncus Holding (HKSE:02216) Gross Profit : HK$47.83 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Broncus Holding Gross Profit?

Broncus Holding's gross profit for the six months ended in Dec. 2024 was HK$24.76 Mil. Broncus Holding's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was HK$47.83 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Broncus Holding's gross profit for the six months ended in Dec. 2024 was HK$24.76 Mil. Broncus Holding's Revenue for the six months ended in Dec. 2024 was HK$34.41 Mil. Therefore, Broncus Holding's Gross Margin % for the quarter that ended in Dec. 2024 was 71.94%.

Broncus Holding had a gross margin of 71.94% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 6 years, the highest Gross Margin % of Broncus Holding was 80.27%. The lowest was 70.47%. And the median was 76.90%.


Broncus Holding Gross Profit Historical Data

The historical data trend for Broncus Holding's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Broncus Holding Gross Profit Chart

Broncus Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial 19.43 68.18 56.95 56.44 47.72

Broncus Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 37.78 31.54 25.00 23.07 24.76

Competitive Comparison of Broncus Holding's Gross Profit

For the Medical Devices subindustry, Broncus Holding's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Broncus Holding's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Broncus Holding's Gross Profit distribution charts can be found below:

* The bar in red indicates where Broncus Holding's Gross Profit falls into.


;
;

Broncus Holding Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Broncus Holding's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=63.206 - 15.485
=47.72

Broncus Holding's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=34.413 - 9.655
=24.76

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$47.83 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Broncus Holding's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=24.76 / 34.413
=71.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Broncus Holding  (HKSE:02216) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Broncus Holding had a gross margin of 71.94% for the quarter that ended in Dec. 2024 => Durable competitive advantage


Broncus Holding Gross Profit Related Terms

Thank you for viewing the detailed overview of Broncus Holding's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Broncus Holding Business Description

Traded in Other Exchanges
N/A
Address
No. 88 Jiangling Road, Xixing Street, Room 801, 8th Floor, Building 8, Binjiang District, Hangzhou, CHN
Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.
Executives
Xu Hong 2101 Beneficial owner
Zi Zhenjun
Xin Nuo Tong Investment Limited 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2101 Beneficial owner
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qm12 Limited 2101 Beneficial owner
Dinova Capital Limited
Dinova Venture Partners Gp Iii, L.p.
Broncus Biomedical Limited
Dinova Healthcare Gamma Fund (usd) L.p.
Computershare Hong Kong Trustees Limited 2301 Trustee
Dinova Healthcare (hong Kong) Co., Limited
Lake Bleu Capital (hong Kong) Limited 2102 Investment manager
Hang Zhou De Nuo Shang Wu Zi Xun Zi Xun You Xian Gong Si

Broncus Holding Headlines

No Headlines